Analysis of Biltamimab and KL1A1 Antibodies for Amyloidosis Treatment

In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis and risk stratification remain a challenge, clinicians and researchers are working to improve upon these. Furthermore, novel immunotherapies are being explored in the field, providing hope for patients.

In this podcast, you will hear from experts Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, and Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, who discuss the latest updates in the treatment and management of AL amyloidosis at the 65th ASH Annual Meeting and Exposition.

The post ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis appeared first on VJHemOnc.